Patents by Inventor Graeme Semple

Graeme Semple has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10624900
    Abstract: Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 21, 2020
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
  • Publication number: 20200078368
    Abstract: Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
    Type: Application
    Filed: March 12, 2019
    Publication date: March 12, 2020
    Inventors: Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
  • Patent number: 10392390
    Abstract: Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 27, 2019
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Albert S. Ren, Graeme Semple, Xiuwen Zhu, Carleton R. Sage
  • Publication number: 20190225612
    Abstract: The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor.
    Type: Application
    Filed: August 18, 2017
    Publication date: July 25, 2019
    Inventors: Graeme Semple, Albert S. Ren, Thomas O. Schrader, Michelle Kasem, Xiuwen Zhu
  • Patent number: 10272094
    Abstract: Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: April 30, 2019
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
  • Publication number: 20180214455
    Abstract: Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Inventors: Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
  • Publication number: 20180186797
    Abstract: Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
    Type: Application
    Filed: April 26, 2016
    Publication date: July 5, 2018
    Inventors: Albert S. Ren, Graeme Semple, Xiuwen Zhu, Carleton R. Sage
  • Patent number: 9676758
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 13, 2017
    Assignee: Arena Pharmaceutical, Inc.
    Inventors: Yifeng Xiong, Andrew J. Grottick, Henry Korman, Juerg Lehmann, Albert S. Ren, Graeme Semple, Didier JC Bagnol
  • Publication number: 20160318911
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 3, 2016
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Yifeng Xiong, Andrew J. Grottick, Henry Korman, Juerg Lehmann, Albert S. Ren, Graeme Semple
  • Patent number: 9365511
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: June 14, 2016
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Jonathan A. Covel, Albert S. Ren, Graeme Semple, Thuy-Anh Tran, Zheng Wei, Yifeng Xiong
  • Publication number: 20150353488
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.
    Type: Application
    Filed: January 8, 2014
    Publication date: December 10, 2015
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Jonathan A. Covel, Albert S. Ren, Graeme Semple, Thuy-Anh Tran, Zheng Wei, Yifeng Xiong
  • Patent number: 8933083
    Abstract: The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: January 13, 2015
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong, Vibha Dave, Mihai D. Azimioara
  • Patent number: 8637555
    Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: January 28, 2014
    Assignees: Arena Pharmaceuticals, Inc., Merck & Co., Inc.
    Inventors: Graeme Semple, Thomas Schrader, Philip J. Skinner, Steven L. Colletti, Tawfik Gharbaoui, Jason E. Imbriglio, Jae-Kyu Jung, Rui Liang, Subharekha Raghavan, Darby Schmidt, James R. Tata
  • Patent number: 8546429
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: October 1, 2013
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc Bruce
  • Patent number: 8410119
    Abstract: The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: April 2, 2013
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Choi, Carleton R. Sage
  • Publication number: 20130023527
    Abstract: The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong, Vibha Dave, Mihai D. Azimioara
  • Patent number: 8293751
    Abstract: The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: October 23, 2012
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Beatriz Fioravanti, Guilherme Pereira, Imelda Calderon, Jane Laguerta Uy, Kameshwari Duvvuri, Jin Sun Karoline Choi, Yifeng Xiong, Vibha Dave, Mihai D. Azimioara
  • Publication number: 20110112060
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: October 13, 2010
    Publication date: May 12, 2011
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc A. Bruce
  • Publication number: 20110082134
    Abstract: The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: November 12, 2010
    Publication date: April 7, 2011
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Robert M. JONES, Graeme SEMPLE, Beatriz FIORAVANTI, Guilherme PEREIRA, Imelda CALDERON, Jane Laguerta UY, Kameshwari DUVVURI, Jin Sun Karoline CHOI, Yifeng XIONG, Vibha DAVE, Mihai D. AZIMIOARA
  • Publication number: 20100331312
    Abstract: Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as excessive daytime sleepiness, narcolepsy, shift-work sleep disorder, drowsiness as a side effect from a medication, maintenance of vigilance to aid in the completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.
    Type: Application
    Filed: February 18, 2009
    Publication date: December 30, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Vincent J. Santora, Brian J. Hofilena, Michelle Pulley, Graeme Semple, Yun Shan, Brian M. Smith